In vivo development of antibody to interferons: an update to 1996.
It has been well established that a percentage of patients receiving interferon (IFN) produce antibodies that can neutralize its action or bind to the molecule. There are also indications that the development of neutralizing antibodies to IFN may be associated with failure of IFN therapy. This article reviews such observations and addresses some of the continuing questions on this issue.